Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18474496 | 0.89 | NOS3 (0.50) | TAAR1CHRNA7HCRTR1HCRTR2HRH3 | |
| SCHEMBL2478342 | 0.83 | SIGMAR1 (0.42) | TAAR1CHRNA7HCRTR1HCRTR2 | |
| SCHEMBL3723569 | 0.80 | CHRNB2 (0.47) | TAAR1HRH3KMT2A | |
| SCHEMBL16213454 | 0.80 | KMT2A (0.49) | TAAR1HCRTR1HCRTR2KMT2A | |
| SCHEMBL25975331 | 0.78 | CHRNA7 (0.52) | TAAR1CHRNA7HRH3NOS3NOS1 | |
| SCHEMBL13430051 | 0.78 | POLB (0.36) | HCRTR1HCRTR2KMT2A | |
| SCHEMBL17048233 | 0.78 | HTT (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL26031611 | 0.77 | CHRNA7 (0.50) | TAAR1CHRNA7HRH3NOS3NOS1 | |
| SCHEMBL16213390 | 0.75 | KDM4E (0.41) | HCRTR1HCRTR2 | |
| SCHEMBL188469 | 0.74 | SMN1; SMN2 (0.44) | HCRTR1HCRTR2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743447-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743178-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025016906-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025016909-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-23 | — | — | WO | disclosed |
| EP-2373657-B1 | 5,7-DIHYDRO-6H-PYRIMIDO[5,4-D][1]BENZAZEPIN-6-THIONES AS PLK INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20150175542-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| EP-2785695-A1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-08 | — | — | EP | disclosed |
| US-20140194410-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8507667-B2 | Thiolactams and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| WO-2013079452-A1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| US-20120309743-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120302551-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8268992-B2 | Thiolactams and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20110257157-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7998952-B2 | Thiolactams and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100179126-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302551-A1 | THIOLACTAMS AND USES THEREOF | PLK3, PLK4, PLK2 | TAAR1 1680/4885CHRNA7 4608/4885HCRTR1 3991/4885 |
| US-20100179126-A1 | THIOLACTAMS AND USES THEREOF | PLK3, PLK4, PLK2 | TAAR1 1680/4885CHRNA7 4608/4885HCRTR1 3991/4885 |
| US-20110257157-A1 | THIOLACTAMS AND USES THEREOF | PLK3, PLK4, PLK2 | TAAR1 1680/4885CHRNA7 4608/4885HCRTR1 3991/4885 |
| US-20150175542-A1 | THIOLACTAMS AND USES THEREOF | PLK3, PLK4, PLK2 | TAAR1 1680/4885CHRNA7 4608/4885HCRTR1 3991/4885 |
| US-20140194410-A1 | THIOLACTAMS AND USES THEREOF | PLK3, PLK4, PLK2 | TAAR1 1680/4885CHRNA7 4608/4885HCRTR1 3991/4885 |
| US-20120309743-A1 | THIOLACTAMS AND USES THEREOF | PLK3, PLK4, PLK2 | TAAR1 1680/4885CHRNA7 4608/4885HCRTR1 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.